A5033074732- Inflammatory Bowel Disease
- Microscopic Colitis
- Colorectal Cancer Screening and Detection
- Liver Diseases and Immunity
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Eosinophilic Esophagitis
- Biosimilars and Bioanalytical Methods
- Surgical Simulation and Training
- Cytokine Signaling Pathways and Interactions
- COVID-19 Clinical Research Studies
- Systemic Sclerosis and Related Diseases
- Ultrasound and Cavitation Phenomena
- Radiomics and Machine Learning in Medical Imaging
- Chronic Disease Management Strategies
- Dermatological and COVID-19 studies
- Diagnosis and treatment of tuberculosis
- Microbial Inactivation Methods
- Pelvic and Acetabular Injuries
- Tuberculosis Research and Epidemiology
- Clinical Nutrition and Gastroenterology
- Medical and Biological Ozone Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal and Anal Carcinomas
- Helicobacter pylori-related gastroenterology studies
King's College Hospital NHS Foundation Trust
2024-2025
King's College Hospital
2021-2025
West Middlesex University Hospital
2018-2019
Chelsea and Westminster Hospital
2019
Imperial College London
2019
Chelsea and Westminster Hospital NHS Foundation Trust
2018
Glasgow Royal Infirmary
2013
Abstract Background Risankizumab is an IL-23 inhibitor which received approval for Crohn’s disease (CD) by the NICE committee in May 2023. Our aim was to evaluate real-world outcomes of risankizumab United Kingdom (UK). Methods We conducted a retrospective, multicentre, cohort study across twenty health boards UK, patients with CD treated between 1st January, 2021 and November 2024. primary outcome treatment persistence at 6 months. secondary endpoints were persistence, steroid-free clinical...
Abstract Background Inflammatory Bowel Disease (IBD) with Liver Transplantation (LT) presents a complex dilemma between disease control versus immunosuppression. The association of IBD and primary sclerosing cholangitis (PSC), alongside increasing metabolic dysfunction-associated fatty liver (MAFLD) in the population, is likely to increase number requiring LT. (1) While immunosuppression therapy post-transplant standardised, proliferation advanced therapies for have unknown efficacy safety...
Abstract Background The PROFILE study demonstrated clear benefits of early advanced therapy in luminal Crohn’s disease (CD) the trial setting. We retrospectively evaluated relationship between timing onset infliximab as first and outcomes a real-world single centre cohort at Oxford University Hospitals NHS Trust. Methods A pharmacy database was searched to identify patients who received CD. Electronic patient records (Cerner) were capture following: demographics, Montreal classification,...
Abstract Background Dye chromoendoscopy (DCE) with targeted biopsies has traditionally been considered the gold standard for optimal detection of dysplasia in context inflammatory bowel disease (IBD) surveillance. Randomised trials have challenged this both virtual (VCE) and high-definition white light endoscopy (WLE) appearing to comparable yield. This multicentre UK study aims test hypothesis that neoplasia rate (NDR) IBD surveillance as part routine clinical care is not affected by...
Objectives Prompt initiation of advanced therapy medications, encompassing biologics and small-molecule treatments, is crucial for the effective management inflammatory bowel disease (IBD). The time taken from decision to start an first administration, or (TAT), can vary significantly between individuals negatively affect course; however, our knowledge causes variation in TAT poor. We aimed investigate impact demographic factors on delays TAT. Methods A retrospective study, conducted at a...
Abstract Aim Colorectal cancer ( CRC ) is diagnosed in approximately 45 000 people annually the UK , and it estimated that Lynch syndrome LS accounts for 3.1% of these cases. In February 2017, National Institute Health Care Excellence NICE guideline DG 27 recommended universal testing new cases mismatch repair MMR status. The aim this study was to implement patients a secondary care setting. Method We prospectively collected data on consecutive newly at our centre from November 2016 August...
Abstract Background Tofacitinib, filgotinib, and upadacitinib are Janus Kinase inhibitors (JAKi) effective in inducing maintaining remission moderate-to-severe ulcerative colitis (UC). Limited data exists regarding outcomes patients on a second JAKi after prior treatment failure. Here we describe the effectiveness of induction with cohort UC patients. Methods In this retrospective study, from 20 UK hospitals treated were included. Clinical endpoints, as defined Table 1, assessed at week 8....
<h3>Introduction</h3> Upadacitinib is a selective Janus kinase inhibitor (JAKi) licenced for use in patients with ulcerative colitis (UC) and effective inducing maintaining remission prior exposure to multiple biologic therapies. However, no evidence exists its efficacy failure tofacitinib. Here we describe case series of highly refractory, steroid dependent UC previous <h3>Methods</h3> We undertook retrospective review clinical data on all (n=5) at least moderately active (SCCAI≥8 UCEIS≥4)...
Abstract Background Personalised medicine approaches are eagerly awaited to facilitate individualisation of medical care for patients with inflammatory bowel disease (IBD). Multiple have already been explored in attempts stratify into different prognostic trajectories. In this study we aimed use machine learning algorithms cluster based on their routinely collected electronic health records an unsupervised approach. Methods We interrogated the rich (EHR) 619 a diagnosis IBD requiring...
Abstract Background Upadacitinib, a selective Janus Kinase inhibitor, is the newest advanced therapy in our armamentarium for treatment of Crohn’s Disease (CD). It has been licensed use moderate-to-severely active CD. However, we have limited evidence its effectiveness ‘real-world’ setting. Methods We undertook retrospective cohort study on CD patients treated with upadacitinib 24 UK hospitals. Clinical endpoints were reviewed at 12 weeks compared to baseline. remission was defined as...
Abstract Background Janus kinase inhibitors (JAKi) licensed for the treatment of inflammatory bowel disease (IBD) now include tofacitinib, upadacitinib and filgotinib. JAKi are known to cause abnormalities in a multitude blood tests. However, whether there differences their effects ‘real-world’ setting is not known. Methods Blood test results 118 patients treated with were collected. A total 13 parameters be affected included. Percentage change at 12 24 weeks from baseline was calculated...
<h3>Introduction</h3> An intensive colonoscopic surveillance programme is proposed in patients with primary or autoimmune sclerosing cholangitis (PSC/AISC) associated inflammatory bowel disease (IBD) because of the high risk colorectal neoplasia (CRN) this group. But, evidence for limited and further exploration into CRN cohort could better inform our practice. We thus aim to describe PSC/AISC-IBD a tertiary centre. <h3>Methods</h3> This retrospective review practice from King's College...
Abstract Text Endoscopic electroporation is a novel technique used in the management of inoperable colorectal and oesophageal cancers. This involves delivery short electrical pulses to tumour tissues, which transiently increases cell membrane permeability, allowing passage calcium ions through open pores give high local cytotoxic effect with minimal adverse systemic effect. In this video we show how treat an locally advanced obstructing sigmoid adenocarcinoma. Clinical result has shown...
<h3>Introduction</h3> Colorectal cancer (CRC) is diagnosed in over 46 000 people the UK annually, and second most common cause of death. NICE guideline DG27 recommends universal testing for Lynch Syndrome (LS) at diagnosis colorectal cancer, by CRC mismatch repair (MMR) status, a hallmark disease. <h3>Methods</h3> We collected data prospectively from November 2016 to December 2017 consecutively patients West Middlesex University Hospital (WMUH) London. CRCs were universally screened tumour...
<h3>Introduction</h3> The gut selective oral beclomethasone dipropionate (Clipper) is approved for use in mild-to-moderate ulcerative colitis (UC), with a better safety profile compared to conventional systemic corticosteroids. We reviewed the efficacy of Clipper inducing clinical remission patients at our Trust. <h3>Methods</h3> collated data on identified though Pharmacy database as receiving prescription from February 2018 2021. Disease activity was determined using Simple Clinical...